Prostate Cancer
Mental health outcomes in a population-based cohort of patients with prostate cancer.
October 24, 2023
Multiparametric MRI characteristics of prostatitis and atrophy in the peripheral zone in men without prostate cancer.
October 24, 2023
Sumitomo Pharma Announces Authorization in Canada of ORGOVYX® (relugolix) for the Treatment of Men with Advanced Prostate Cancer
October 23, 2023
PSMA-PET in Addition to mpMRI and Biopsies to Select Prostate Cancer Patients for Focal Therapy.
October 23, 2023
Long-Term Nephrotoxicity of 177Lu-PSMA Radioligand Therapy.
October 23, 2023
Analysis of active surveillance uptake for localized prostate cancer in Quebec in 2016: A Canadian bicentric study and comparison with 2010 data.
October 23, 2023
Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer.
October 20, 2023
Clinical stage and grade migration of localized prostate cancer at diagnosis during the past decade.
October 20, 2023
Health-Related Quality of Life Assessment in Prostate Cancer Patient Undergoing Androgen Deprivation Therapy: Real-World Experience in the READT Study.
October 20, 2023
Oncological Outcomes of Patients with High-Volume mCRPC: Results from a Longitudinal Real-Life Multicenter Cohort.
October 19, 2023
Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
October 19, 2023